1. Home
  2. |Insights
  3. |Pay-to-Play 2: CFIUS Filing Fees Go Into Effect May 1, 2020

Pay-to-Play 2: CFIUS Filing Fees Go Into Effect May 1, 2020

Client Alert | 1 min read | 04.28.20

The Committee on Foreign Investment in the US (CFIUS) has announced an Interim Final Rule requiring payment of filing fees in connection with any Joint Voluntary Notices submitted on or after May 1, 2020 for “covered transactions” under 31 C.F.R. Part 800 or for “covered real estate transactions” under Part 802. The Interim Final Rule adopts, without change, the sliding scale fee structure as initially proposed, but in light of the COVID-19 pandemic, will continue to accept comments until June 1, 2020.

The fee schedule is:

Total Transaction Value

Filing Fee

< $500,000

$0

> $500,000 but < $5 million

$750

> $5 million but < $50 million

$7,500

> $50 million but < $250 million

$75,000

> $250 million but < $750 million

$150,000

> $ 750 million

$300,000


CFIUS rejected comments seeking to limit the transaction value to just the value of the U.S. business and denied concerns that the lack of any fee for submission of mandatory or voluntary declarations would provide a financial or administrative incentive for CFIUS to fail to conclude action under Section 721 of the Defense Production Act in evaluating such declarations.

Contacts

Insights

Client Alert | 5 min read | 04.23.26

CMS Proposes New Payment Policy for IOPOs and HCLs

In keeping with ongoing efforts to intensify regulatory oversight of organ procurement organizations (OPOs) and curtail improper spending within federal health programs, the Centers for Medicare & Medicaid Services (CMS) recently issued a proposed rule that would, among other adjustments, align Medicare payment policies for non-renal organs to be consistent with those currently applicable to kidneys. If enacted as drafted, this latest rule could have a direct impact on the financial stability of OPOs and histocompatibility laboratories (HCL) at a time when such organizations face increasing pressure to meet CMS’s new outcome measures — or else face non-renewal or decertification later this year. ...